Reuters logo
BRIEF-Alder Biopharma says its single IV dose of ALD403 shows efficacy in treating migraine
May 15, 2015 / 12:21 PM / 2 years ago

BRIEF-Alder Biopharma says its single IV dose of ALD403 shows efficacy in treating migraine

May 15 (Reuters) - Alder Biopharmaceuticals Inc

* Announced six-month follow-up data from phase 2 proof-of-concept clinical trial of ald403

* Single iv dose of ald403 demonstrates efficacy over six months for preventive treatment of migraine Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below